Skip to main content

Advertisement

Log in

Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The published data on the predictive value of polymorphism of ERCC1 and XPD in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Relevant studies were identified by searching the Medline, Embase, CNKI and American Society of Clinical Oncology abstract databases. Inclusion criteria were patients with advanced NSCLC, received platinum-based chemotherapy, evaluation of polymorphism of ERCC1 and XPD and overall response rate (ORR). A total of 12 studies were included in this meta-analysis. For studies evaluating ERCC1 polymorphism at codon 118, the ORR for the wild-type C/C genotype versus the heterozygous C/T and T/T genotype was 2.17 (95% confidence interval (CI), 1.43–3.33; P = 0.000). For studies evaluating XPD Asp312Asn and XPD Lys751Gln, the pooled OR was 1.33 (95% CI, 0.92–1.91; P = 0.13) and 1.02 (95% CI, 0.72–1.45; P = 0.915), respectively. The results indicated that platinum-based chemotherapy sensitivity was significantly associated with polymorphism of ERCC1 C118T. However, XPD Asp312Asn and XPD Lys751Gln were not predictive makers for platinum-based chemotherapy in patients with advanced NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Evans T. Chemotherapy in advanced non-small cell lung cancer. Semin Respir Crit Care Med. 2005;26:304–13. doi:10.1055/s-2005-871989.

    Article  PubMed  Google Scholar 

  2. Furuta T, Ueda T, Aune G, et al. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. 2002;62:4899–902.

    PubMed  CAS  Google Scholar 

  3. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983–91.

    Article  PubMed  CAS  Google Scholar 

  4. Chen J, Larochelle S, Li X, et al. Xpd/Ercc2 regulates CAK activity and mitotic progression. Nature. 2003;424:228–32. doi:10.1038/nature01746.

    Article  PubMed  CAS  Google Scholar 

  5. Rosell R, Taron M, Ariza A, et al. Molecular predictors of response to chemotherapy in lung cancer. Semin Oncol. 2004;31:20–7. doi:10.1053/j.seminoncol.2003.12.011.

    Article  PubMed  CAS  Google Scholar 

  6. Gazdar AF. DNA repair and survival in lung cancer—the two faces of Janus. N Engl J Med. 2007;356:771–3.

    Article  PubMed  CAS  Google Scholar 

  7. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2006;12:1294–300. doi:10.1038/nm1491.

    Article  PubMed  CAS  Google Scholar 

  8. Mantel NH. Statistical aspect of the analysis of data from retrospective studies of disease. Natl Cancer Inst. 1959;22:719–48. doi:10.1016/0021-9681(79)90031-6.

    CAS  Google Scholar 

  9. Zhou C, Ren S, Zhou S, et al. Genotyping single-nucleotide polymorphisms (SNPs) in ERCC1 and XRCC3 genes for efficacy prediction in chemotherapy of non-small cell lung cancer (NSCLC). J Clin Oncol. 2008;26.

  10. Camps C, Sarries C, Roig B, et al. Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients. Clin Lung Cancer. 2003;4:237–41. doi:10.3816/CLC.2003.n.004.

    Article  PubMed  CAS  Google Scholar 

  11. Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol. 2004;15:1194–203. doi:10.1093/annonc/mdh319.

    Article  PubMed  CAS  Google Scholar 

  12. Ryu JS, Hong YC, Han HS, et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer. 2004;44:311–6. doi:10.1016/j.lungcan.2003.11.019.

    Article  PubMed  Google Scholar 

  13. Yuan P, Miao XP, Zhang XM, et al. XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 2006;28:196–9.

    PubMed  CAS  Google Scholar 

  14. Booton R, Ward T, Heighway J, et al. Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer. Cancer. 2006;106:2421–7. doi:10.1002/cncr.21885.

    Article  PubMed  CAS  Google Scholar 

  15. Song DG, Liu J, Wang JH, et al. XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer. Chin J Gerontol. 2007;1684-86.

  16. Su D, Ma S, Liu P, et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer. 2007;56:281–8. doi:10.1016/j.lungcan.2006.12.002.

    Article  PubMed  Google Scholar 

  17. Fan H, Jin GF, Shen HB. Relationship of XRCC1 and XPD gene polymorphisms with chemosensitivity to platinum-based chemotherapy in advanced non-small cell lung cancer. Pract Geriatr. 2008;22:306–14.

    CAS  Google Scholar 

  18. Tibaldi C, Giovannetti E, Vasile E, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 2008;14:1797–803. doi:10.1158/1078-0432.CCR-07-1364.

    Article  PubMed  CAS  Google Scholar 

  19. Kalikaki A, Kanaki M, Vassalou H, et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer. 2009;10:118–23. doi:10.3816/CLC.2009.n.015.

    Article  PubMed  CAS  Google Scholar 

  20. Gandara DR, Kawaguchi T, Crowley J, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol. 2009;27:3540–6.

    Article  PubMed  CAS  Google Scholar 

  21. Lenz HJ. The use and development of germline polymorphisms in clinical oncology. J Clin Oncol. 2004;22:2519–21. doi:10.1200/JCO.2004.04.900.

    Article  PubMed  CAS  Google Scholar 

  22. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev. 2008;24:331–44.

    Article  Google Scholar 

  23. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1513–30.

    PubMed  CAS  Google Scholar 

  24. Yu JJ, Mu C, Lee KB, Okamoto A, et al. A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat Res. 2007; 382:13–20. doi:10.1016/S1383-5726(97)00004-6.

    Google Scholar 

  25. Evans E, Moggs JG, Hwang JR, et al. Mechanism of open complex and dual incision formation by human nucleotide excision repair factors. EMBO J. 1997;16:6559–73. doi:10.1093/emboj/16.21.6559.

    Article  PubMed  CAS  Google Scholar 

  26. Kiyohara C, Yoshimasu K. Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis. Int J Med Sci. 2007;4:59–71.

    PubMed  CAS  Google Scholar 

  27. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol. 2004;22:2594–601. doi:10.1200/JCO.2004.08.067.

    Article  PubMed  CAS  Google Scholar 

  28. Wei Q, Frazier ML, Levin B. DNA repair: a double-edged sword. J Natl Cancer Inst. 2000;92:440–1.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yong Song.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wei, Sz., Zhan, P., Shi, Mq. et al. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol 28, 315–321 (2011). https://doi.org/10.1007/s12032-010-9443-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9443-1

Keywords

Navigation